Prolonged QTc intervals on admission electrocardiograms: Prevalence and correspondence with admission electrolyte abnormalities

Connecticut Medicine

Volumn 71, Issue 7, 2007, Pages 389-397

  Golzari, Houtan ^a,b,c   Dawson, Neal V ^a   Speroff, Ted ^d   Thomas, Charles ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c ST VINCENT S MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELECTROLYTE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHI SQUARE DISTRIBUTION; COMORBIDITY; CROSS-SECTIONAL STUDY; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; LONG QT SYNDROME; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; STATISTICAL MODEL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; ELECTROLYTES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; LINEAR MODELS; LONG QT SYNDROME; MALE; MIDDLE AGED; OHIO; PREVALENCE;

EID: 34547801632     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Ben-David J, Zipes DP; Torsades de pointes and proarrhythmia. Lancet 1993; 341:1578-82.
2. Moss AJ, Schwartz PJ, Crampton RS, et al: The long QT syndrome, prospective longitudinal study of 328 families. Circulation 1991; 84:1136-44.
3. Pacia SV, Devinsky O, Luciano DJ, Vazquez B: The prolonged QT syndrome presenting as epilepsy: A report of two cases and literature review. Neurology 1994; 44:1408-10.
4. Morganroth J: Relations of QTc prolongation on the electrocardiogram to torsades de pointes: Definitions and mechanisms. Am J Cardiol 1993; 72:10B-13B.
5. Faber TS, Zehender M, Just H: Drug-induced torsades de pointes. Incidence, management and prevention. Drug Saf 1994; 11:463-76.
6. Stratmann HG, Kennedy HL: Torsades de pointes associated with drugs and toxins: Recognition and management. Am heart J 1987; 113:1470-82.
7. Brandriss MW, Richardson WS, Barold SS: Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): Case report and review. Clin Infect Dis 1994; 18:995-8.
8. Morganroth J, Brown AM, Critz S, et al: Variability of the QTc interval: Impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 1993; 72:26B-31B.
9. Koh KK, Rim MS, Yoon J, Kim SS: Torsades de pointes induced by terfenadine in a patient with long QT syndrome. J Electrocardiol 1994; 27:343-6.
10. Rao KA, Adlakha A, Verma-Ansil B, et al: Torsades de pointes ventricular tachycardia associated with overdose of aztemazole. Mayo Clin Proc 1994; 69:589-93.
11. Schrem SS, Belsky P, Schwartzman D, Slater W: Cocaine-induced torsades de pointes in a patient with the idiopathic long QT syndrome. Am Heart J 1990; 120:980-4.
12. Schouten EG, Dekker JM, Meppelink P, et al: QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991; 84:1516-23.
13. Goldberg RJ, Bengtson J, Chen Z, et al: Duration of the QT interval and total and cardiovascular mortality in healthy persons (the Framingham heart study experience). Am J Cardiol 1991; 67:55-8.
14. Bronsky D, Dubin A, Kushner DS, Waldstein SS: Ca and the electrocardiogram. Am J Cardiol 1961; 7:840-3.
15. Ahmed R, Kiya F, Kitano K, et al: Effects of combined changes in serum calcium and potassium on QT interval. Jpn Heart J 1987; 28:813-28.
16. Zane EA, Eisenkraft JB, Haimov M: Hypocalcemia and prolonged QT interval following carotid artery surgery. Anesthesiology 1987; 67:998-1000.
17. Howard EJ: Value of the QT interval. Am Heart J 1960; 59:789-90.
18. Curry P, Fitchett D, Stubbs W, Krikler D: Ventricular arrhythmias and hypokalemia. Lancet 1976; 2:231-3.
19. Giustiniani S, Robustelli della Cuna F, Sardeo C, Forni MC: "Torsade de Pointes" induced by hypocalcemia. G Ital Cardiol 1982; 12:889-91.
20. Akiyama T, Batchelder J, Worsman J, et al: Hypocalcemic torsades de pointes. J Electrocardiol 1989; 22:89-92.
21. Surawicz B, Knoebel SB: Long QT: Good, bad or indifferent? J Am Coll Cardiol 1984; 4:398-413.
22. Chung EK: Electrolyte imbalance. Intern Med 1996; Feb 92-101.
23. Kulkarni P, Bhattacharya S, Petros AJ: Torsades de pointes and long QT syndrome following major blood transfusion. Anesthesia 1992; 47:125-7.
24. Seymour JF: Induction of hypomagnesemia during amsacrine treatment. Am J Hem 1993; 42:262-7.
25. Nunoda S, Ueda K, Kameda S, Nakabayashi H: Sheehan's syndrome with hypomagnesemia and polymorphous ventricular tachycardia, Jpn Heart J 1989; 30:251-6.
26. Ramee SR, White CJ, Svinarich JT, et al: Torsade de pointes and magnesium deficiency. Am Heart J 1985; 109:164-7.
27. Topol EJ, Lerman BB: Hypomagnesemic torsades de pointes. Am J Cardiol 1983; 52:1367-8.
28. Grant HI, Yeston NS: Cardiac arrest secondary to emotional stress and torsade de pointes in a patient with associated magnesium and potassium deficiency. Crit Care Med 1992; 19:292-4.
29. Kannel WB, Cupples LA, D'Agostino RB, Stokes J 3rd: Hypertension, antihypertensive treatment, and sudden coronary death. The Framingham study. Hypertension II 1988; (SUPP II): II-45-II-50.
30. Singh BN, Hollenberg NK, Poole-Wilson PA, Robertson JLS: Diuretic-induced potassium and magnesium deficiency: Relation to drug-induced QT prolongation, cardiac arrhythmia and sudden death. J Hypertens 1992; 10:301-16.
31. Surawicz B: Is hypomagnesemia or magnesium deficiency arrhythmogenic? J Am Coll Cardiol 1989; 14:1093-6.
32. Tzivoni D, Banai S, Schuger C, et al: Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77:392-7.
33. McLean RM: Magnesium and its therapeutic uses: A review. Am J Med 1994; 96:63-76.
34. Seelig M: Cardiovascular consequences of magnesium deficiency and loss: Pathogenesis, prevalence and manifestations-magnesium and chloride loss in refractory potassium repletion. Am J Cardiol 1989; 63:4G-21G.
35. Goldman MJ: Principles of Clinical Electrocardiography. 10th ed. Los Altos (CA): Lange Medical Publications; 1979.
36. Commerford PJ, Lloyd EA: Arrhythmias in patients with drug toxicity, electrolyte, and endocrine disturbances. Med Clin North Am 1984; 68:1051-78.
37. SAS Institute Inc., SAS/STAT User's Guide. Version 6, Fourth Edition, Volume 1, Cary, NC: SAS Institute Inc., 1989:823-50.
38. Havrell FE: Predicting Outcomes: Applied Survival Analysis and Logistic Regression. In Book Manuscript, University of Virginia, Charlottesville, VA 1999:31-8.
39. Moss AJ: Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol 1993; 72:23B-25B.
40. MacFarlane PW, Lawrie TDV: Comprehensive Electrocardiography: Theory and Practice in Health and Disease. New York: Pergamon Press; 1989:1142.
41. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA: Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991; 67:774-6.
42. Garson Jr, A: How to measure the QT interval - what is normal? Am J Cardiol 1993; 72:14B-16B.
43. Rautaharju PM, Manolio TA, Psaty BM, et al: Correlates of QT prolongation in older adults (the cardiovascular health study). Am J Cardiol 1994; 73:999-1002.
44. Diaz-Rivera RS, Ramos-Morales F, Garcia-Palmieri MR, Ramirez EA: The electrocardiographic changes in acute phosphorous poisoning in man. Am J Med Sci 1961; 241:758-65.
45. Kirschbaum B: The acidosis of exogenous phosphate intoxication, Arch Intern Med 1998; 158:405-8.
46. Bexton RS, Vallin H, Camm AJ: Diurnal variation of the QT interval: Influence of the autonomic nervous system. Br Heart J 1984; 51:694.
47. Murakawa Y, Inoue H, Nozaki A, Sugimoto T: Role of sympathovagal interaction in diurnal variation of QT interval. Am J Cardiol 1992; 69:340-3.
48. Lipicky RJ: A viewpoint on drugs that prolong the QTc interval. Am J Cardiol 1993; 72:53B-54B.
49. Hohnloser SH, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects. A review with special reference to torsades de pointes tachycardia.Ann Intern Med 1994; 121:529-35.
50. Wang MH, Tseng CD, Bair SY: Q-T interval prolongation and polymorphic ventricular tachyarrhythmia (Torsades de pointes) in organophosphate poisoning; Report of a case. Hum Exp Toxicol 1998; 10:587-90.
51. Straus SM, Sturkenboom MC, Bleumink GS, etal: Noncardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005; 26(19):2007-12.
52. Fiset C, Kargacin ME, Kondo CS, et al: Hypomagnesemia: Characterization of a model of sudden cardiac death. J Am Coll Cardiol 1996; 27:1771-6.
53. Moore EN: Mechanisms and mode to predict a QTc effect. Am J Cardiol 1993; 72:4B-9B.
54. Abinader EG, Shahar J: Possible female preponderance in prenylamine-induced "Torsade de Pointes" tachycardia. Cardiology 1983; 70:37-40.
55. Wysowski DK, Bacsanyi J: Cisapyride and fatal arrhythmia. New Eng J Med 1996; 335:290-291, 1996.
56. Thomas AR, Chan LN, Bauman JL, Olopade CO: Prolongation of the QT Interval Related to cisapride-diltiazem interaction. Pharmacotherapy 1998; 18:381-5.
57. Dujovne CA, Atkins F, Wong B, et al: Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol 1984; 26:735-9.
58. Stramba-Badiale M, Nador F, Porta N, et al: QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am Heart J 1997; 133:108-11.
59. Ikeda T: QT prolongation in type 2 diabetes mellitus treated with glibenclamide. Diabetes Metab 1004; 6:565-7.
60. Stambler BS, Wood MA, Ellenbogen KA, et al and the ibutilide repeat dose study investigators: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation, Circulation 1996; 94:1613-21.
61. Falk RH, Pollak A, Singh SN, Friedrich T: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J AM Coll Cardiol 1997; 29:385-90.
62. Benedict CR, Arbogast R, Martin L, et al: Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996; 1:53-9.
63. Gatifloxacin and moxifloxacin: Two new fluoroquinolones. The Medical Letter 2000; 42:15-17.
64. Pratt CM, Mason J, Russell T, et al: Cardiovascular safety of fexofenadine HCL. Am J Cardiol 1999; 83:1451-1454, 1999.
65. Gabel A, Schymik G, Mehmel HC: Ventricular fibrillation due to long QT syndrome probably caused by clindamycin. Am J Cardiol 1999; 83:813-5.
66. Canadian Adverse Drug Reaction Newsletter. Drugs causing prolongation of QT interval and torsades de pointes. CMAJ 1998; 8:103-4.
67. Michaloudis D, Fraidakis O, Petrou A, et al: Anaesthesia and the QT interval, effect of isoflurane and halothane in unpremedicated children. Anaesthesia 1998; 53:435-9.
68. Wharton JM, Demopulos PA, Goldschlager N: Torsades de pointes during administration of pentamidine isethionate. Am J Med 1987; 83:571-6.
69. Funck-Brentano C, Jaillon P: Rate-corrected QT interval: Techniques and limitations. Am J Cardiol 1993; 72:17B-22B.